[Management of bone metastasis originating from lung cancer].
The preceding molecular target therapies have prolonged the life expectancy of many lung cancer patients, and some lung cancer patients have become long-term survivors. On the other hand, the proportion of patients who suffer from complications with bone metastasis and skeletal-related events(SRE)is increasing. Through management of bone metastasis, the preservation of quality of life and functional independence can be better maintained. Zoledronic acid and denosumab are usable in clinical practice; However, there are many problems in regard to treatments for bone metastasis. Lung cancer patients should be treated with bone metastasis with the coordinating cooperation between orthopedists, radiotherapists and dental surgeons.
Dept. of Medicine II, Niigata University Medical and Dental Hospital, Japan.
Satoru
S
Miura
Hiroshi
H
Kagamu
Yasuo
Y
Saijyo
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D011788:Quality of Life; D000077211:Zoledronic Acid
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000069448:Denosumab; D000077211:Zoledronic Acid